drugset / Trial / NCT05266417

Intranasal Insulin and Glutathione as an Add-On Therapy in Parkinson's Disease

NCT05266417

Phase 2 Recruiting 56 enrolled Gateway Institute for Brain Research
RandomizedParallel-groupTriple-blindTreatment

Summary

This study will be evaluating the safety and efficacy of insulin and glutathione in subjects with Parkinson's Disease compared to placebo.

Timeline

Start
2022-02-07
Primary completion
2027-01-01
Completion
2027-07-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Glutathione Peptide Intranasal
Subject Insulin Protein / enzyme biologic Intranasal

Indications